Human EGFR Knockout Cell Line-HEK293T
Cat.No. : CSC-RT2769
Host Cell: HEK293T Target Gene: EGFR
Size: 1x10^6 cells/vial, 1mL Validation: Sequencing
Inquire for Price
Cell Line Information
Cell Culture Information
Safety and Packaging
| Cat. No. | CSC-RT2769 |
| Cell Line Information | This cell is a stable cell line with a homozygous knockout of human EGFR using CRISPR/Cas9. |
| Target Gene | EGFR |
| Host Cell | HEK293T |
| Size Form | 1 vial (>10^6 cell/vial) |
| Shipping | Dry ice package |
| Storage | Liquid Nitrogen |
| Species | Human |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Media Type | Cells were cultured in DMEM supplemented with 10% fetal bovine serum. |
| Growth Properties | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Split at 80-90% confluence, approximately 1:3-1:6. |
| Freeze Medium | Complete medium supplemented with 10% (v/v) DMSO |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Inquiry
Background
Applications
The PITPNA gene, also known as phosphatidylinositol transfer protein Alpha, is a member of the phosphatidylinositol transfer protein (PITP) family and plays a crucial role in lipid signaling and metabolism. The PITPNA gene is located on chromosome 17p13.3 in humans and chromosome 11 B5 in mice. The protein encoded by PITPNA is expressed in various tissues, with higher levels in the retinal pigment epithelium, parotid gland, pons, and specific regions of the skin and brain. One of the main functions of the PITPNA protein is to bind and transfer phosphatidylinositol (PI) and phosphatidylcholine (PC) between cell membrane compartments. This transport process is essential for the synthesis of phosphoinositides, which are key signaling molecules that regulate various cellular activities, including cell growth, differentiation, and survival.
Research has shown that the PITPNA gene plays an important role in neural development and function. Mutations or defects in this gene have been associated with a variety of neurological diseases. For example, alterations in PITPNA expression can affect synaptic function and plasticity, which can lead to cognitive impairment and neurodegenerative diseases. In addition to its neurological importance, PITPNA has been implicated in other physiological processes. The gene has been observed to be involved in regulating insulin secretion from pancreatic beta cells, highlighting its potential link to metabolic disorders such as diabetes.
Cancer Research: HEK293T cells lacking EGFR can be used to study mechanisms of tumor progression, signal transduction pathways, and cellular responses to anti-EGFR therapies.
Drug Screening and Development: EGFR knockout HEK293T cell lines are powerful models for high-throughput screening of potential therapeutics. By determining how drugs interact in the context of EGFR deficiency, researchers can isolate EGFR-independent mechanisms, which can aid in the development of more precise inhibitors with fewer side effects.
Study Cell Signaling: EGFR plays a key role in a variety of signaling pathways. Knockout cell lines help distinguish EGFR-specific signaling from other receptor-mediated signaling. This can help provide a more nuanced understanding of cellular communication networks and identify new therapeutic targets.
Toxicity Testing: These cells allow the evaluation of the cytotoxic effects of new compounds in the context of controlled EGFR deficiency. This is critical to ensuring the safety and efficacy of new therapies before moving to clinical trials.
For research use only. Not intended for any clinical use.
